European Union criticised for health policies towards developing countriesBMJ 2009; 339 doi: http://dx.doi.org/10.1136/bmj.b4328 (Published 21 October 2009) Cite this as: BMJ 2009;339:b4328
- Rory Watson
The European Union has been accused this week of applying double standards, by trying to reduce the price of generic drugs within its own borders while preventing developing countries from enjoying the same benefits.
The criticism is contained in a report published by Oxfam and Health Action International Europe on 20 October. The two organisations maintain that the EU is insisting on tough new intellectual property rights for the benefit of drug companies in the bilateral free trade agreements that it is negotiating with developing countries.
This, they say, will lead to higher prices for drugs. Citing an accord between the EU …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial